On July 13, 2026, the Alzheimer's Association announced the $100 million PROTECT-Cog prevention trial at AAIC 2026 in London in the Association announcement. PROTECT-Cog means Prevention of Risk fOr cogniTive dEcline through Combined Therapy, per the Association release, and spouses can ask about fit, burden and follow-up. Medscape notes enrollment focuses on older adults at higher risk who remain cognitively unimpaired. The aim is to slow decline and prevent mild cognitive impairment and dementia before symptoms begin, as Medscape reported in its trial overview.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Is This Trial For?
- What Will Participation Require?
- What Do Earlier Results Suggest?
- What Should Partners Ask Next?
Who Is This Trial For?
PROTECT-Cog is an early-prevention study, not a treatment study. It targets people without memory symptoms who carry higher risk for later decline.
For partners, the question is whether prevention fits now. Ask whether both of you can support diet, exercise and training changes before symptoms demand care.
- older adult without cognitive impairment
- higher risk for cognitive decline
- able to attend coaching and health checks over 3 years
What Will Participation Require?
Participants enter either intensive coaching or a structured-lite version with the same core content, as NeurologyLive reported in its trial summary. NeurologyLive reports a smaller subset also receives drug therapy, with cognitive and health checks every 6 months for 3 years. Planning starts with time, drugs and updates, and written answers help later choices.
A pharmaphorum summary of the Association announcement frames the same practical points for families weighing enrollment. Ask for the visit calendar and contact plan in writing. Keep copies where both partners can find them during the 3-year schedule.
- How many coaching meetings, including the intensive 38-meeting style schedule, and what happens if we miss sessions?
- Who may receive active drug versus placebo, what side effects require a call, and who covers safety checks?
- How often are 6-month tests scheduled, how are mild cognitive impairment, frailty and safety findings shared, and who sees them?
What Do Earlier Results Suggest?
NeurologyLive places PROTECT-Cog after U.S. POINTER, trial NCT03688126, a 2-year study in 2,111 at-risk adults with mean age 68.2. Structured exercise, MIND eating plan, cognitive training and vascular care raised global cognition by 0.029 standard-deviation units per year versus self-guided care.
NeurologyLive notes caution from EVOKE and EVOKE+, with 3,808 participants, where oral semaglutide lowered inflammation, including about 30% lower CRP. CRP is a blood marker of inflammation, but treatment did not slow decline on the CDR-SB dementia scale, and the extension stopped. For partners, the takeaway is direct. Lifestyle helped modestly on average in POINTER, a metabolic pill alone did not slow decline in EVOKE, and the combined approach still needs testing.
What Should Partners Ask Next?
Medscape reported that the exact metabolic agent, eligibility rules, sites and start dates were not final at announcement. That means you cannot enroll yet or assume who would receive active drug. Use the waiting period to clarify duties, travel and backup support.
Bring a short list so the first screening visit stays focused. Write down work schedules, travel limits and backup care for 3 years. Then compare them with the meeting and testing calendar when it posts.
- When will sites, dates and final eligibility post, and where do we sign for updates?
- Which drug and dose is chosen, who is excluded for safety, and what happens with placebo?
- How will you share mild cognitive impairment, frailty and safety results with us and our clinician?
You Might Also Like
- Dementia Subtype Data Gaps Identified by NIA in 2026: Questions Adults With Memory Concerns Can Ask About the Research
- Privacy and Data Access Gaps in 2026 Dementia Research: Questions Adults With Memory Concerns Can Ask About the Research
- NIA’s 2026 Late-Life Depression and Dementia Workshop: Questions Adults With Memory Concerns Can Ask About the Research
